Updated:
Greenphire
Greenphire launched in 2008 when Sam Whitaker and his co-founders identified a structural gap in clinical research: sites were spending 30% of coordinator...
Greenphire
Greenphire launched in 2008 when Sam Whitaker and his co-founders identified a structural gap in clinical research: sites were spending 30% of coordinator time on manual payment reconciliation rather than patient care. The company built ClinCard, a reloadable debit-card system that replaced paper checks and petty cash for patient reimbursement, then layered on eClinicalGPS for site payments and ConneX for patient travel. By 2017 the platform was processing payments in over 90 countries. The company's product suite covers the full clinical-trial payment lifecycle — patient stipends and travel reimbursements (ClinCard, ConneX), investigator and site grant payments (eClinicalGPS), and trial-level budget management. Greenphire sells exclusively to biopharma sponsors and contract research organizations, not directly to sites. Its client list includes 28 of the 30 largest pharmaceutical companies globally and the majority of top-tier CROs. The platform supports over 50,000 active studies across 140 countries, handling 42 different currencies through an integrated compliance layer that manages tax withholding, fair market value, and anti-bribery requirements for every transaction. The business was acquired by The Riverside Company in 2015, then sold to Thoma Bravo in 2021 in a deal reported at over $1.1 billion (per PE Hub, 2021). Since the Thoma Bravo acquisition, Greenphire has launched Greenphire Direct, a patient-convenience offering that provides rideshare and meal delivery integration directly through the ClinCard interface, and has deepened its integration with major electronic data capture and clinical trial management systems. In 2023 the company processed over $4.5 billion in clinical trial payments across its platform (per the firm's official communications, 2023). Headcount has not been publicly disclosed, though the firm operates primarily from King of Prussia with a distributed workforce. Greenphire's structural differentiator is its role as the de facto payment rail for the clinical trial industry. By embedding compliance automation — 1099 generation, FMV rate cards, anti-bribery screening — directly into the payment flow, the platform serves as a closed-loop system that eliminates separate accounting reconciliation workflows. This makes the software deeply sticky: once a sponsor or CRO standardizes on Greenphire's payment infrastructure across a portfolio of trials, switching costs are high and the data generated on patient enrollment velocity and site performance becomes an ancillary asset for portfolio planning.
General information
Firm type
other
Year founded
2008
AUM
Undisclosed
Location
Region
North America
Country
United States
City
King of Prussia
Corporate office
King of Prussia, PA, United States
Principals
Sam Whitaker
Chief Executive Officer
Jim Murphy
Chief Revenue Officer
Sector focus
Frequently asked questions
How does Greenphire generate revenue?
Greenphire operates on a SaaS subscription model, charging pharmaceutical sponsors and CROs based on the number of active studies using its platform and the volume of payments processed. The company does not earn interchange fees on ClinCard transactions; revenue comes from software licensing and services fees, which creates alignment with clients on minimizing payment friction rather than maximizing transaction volume.
Who owns Greenphire now?
Thoma Bravo acquired Greenphire in 2021 from The Riverside Company in a deal reported at over $1.1 billion (per PE Hub, 2021). The acquisition reflects Thoma Bravo's thesis that clinical-trial payment infrastructure is a mission-critical software category with high switching costs and a long runway for consolidation.
What does Greenphire's competitive landscape look like?
The clinical-trial payment automation market includes point-solution competitors like ClinEdge (patient payments) and PaymentWorks (site payments), as well as broader clinical technology platforms such as IQVIA and Veeva that could build payment modules. Greenphire's advantage is its installed base across most of the top pharmaceutical sponsors, which creates a network effect: CROs and sites prefer to work with a standardized payment platform rather than managing multiple sponsor-specific payment processes.
How does Greenphire handle regulatory compliance across different countries?
The platform integrates tax withholding rules, fair market value rate cards, and anti-bribery requirements (including FCPA and UK Bribery Act) for each of the 140 countries where it processes payments. This compliance layer is built directly into the payment workflow, meaning individual transactions are automatically validated against local regulations before funds are released to sites and patients.
Does Greenphire sell directly to clinical research sites?
No. Greenphire sells exclusively to biopharmaceutical sponsors and contract research organizations (CROs). Sites and patients interact with the platform as end users — patients receive ClinCard debit cards, and site coordinators use the portal for reconciliation — but the buyer and licensee is always the sponsor or CRO.
What payment methods does Greenphire support?
ClinCard uses reloadable physical debit cards as the primary patient payment method, with virtual card and direct deposit options available in certain markets. Site and investigator payments flow through eClinicalGPS, which supports ACH, wire transfer, and local bank-payment rails across 42 currencies. The platform does not use paper checks or petty cash, which were the industry standard before Greenphire's entry.
Has Greenphire made any acquisitions?
Greenphire acquired Cullman Technologies, a clinical trial travel and logistics provider, in 2016, which formed the foundation for what became the ConneX travel-management module. The company has not publicly disclosed additional acquisitions since, though under Thoma Bravo ownership it is widely expected to pursue add-on acquisitions that expand its clinical-trial workflow footprint.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: